UpadacitinibvedolizumabinfliximabadalimumabustekinumabUPAulcerative colitisCrohn’s diseaseUC
…Upadacitinib (UPA) is a novel orally administered small molecule drug that w…
90articles mentioning drugs
234drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: infliximab ×
infliximab
This drug is selected. Its supporting articles are shown below.
Articles mentioning infliximab
90 articles · page 8 of 8UstekinumabVedolizumabRisankizumabTNFiinfliximabinflammatory bowel diseaseIBDileocolonic disease
…ent followed by another anti-TNFa treatment or Vedolizumab then Ustekinumab. Median age at diagnosis was 8 years. We found that (40%) switc…
UstekinumabAdalimumabInfliximabTofacitinib
…29 children had significant IBD clinical symptoms when starting Ustekinumab. 16/20 (80%) saw some improvements at 3 months. At 6 months 8/2…
abataceptinfliximabtocilizumabMethylprednisolonetacrolimusmycophenolate mofetilnon-small cell lung cancermelanomaMyocarditisCochrane+3 more
…nd 3L settings (1/17); tacrolimus, mycophenolate mofetil (MMF), abatacept, infliximab in 1L or 2L setting without any evidence of compara…
infliximabvedolizumabinflammatory bowel diseasecoeliac diseasethyroiditiscancerenteritiscombination immunotherapy
…iological medications for corticosteroid refractory cases. Both infliximab and vedolizumab have demonstrated efficacy in excess of 80% of …
infliximabdupilumabdapsoneJanus kinase (JAK) inhibitorsprurigo nodularisatopic dermatitiseczematous dermatitistumour necrosis factor-alpha (TNFα) inhibitorsneutrophilic dermatosissubcorneal pustular dermatosis+1 more
… experienced a dramatic and sustained clinical improvement with infliximab. This case highlights the diagnostic challenges posed by atypic…